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Abstract
PDDTE are tracked by the OPTN Ad Hoc DTAC. Specific evaluation of potential transmis-
sions from pediatric deceased donors or the impact of donor- derived disease transmis-
sions to pediatric organ recipients has not been previously undertaken. PDDTE reported 
to the DTAC between 2008 and 2013 were reviewed, characterized as proven, probable, 
possible, IWDT, unlikely, or excluded for both the whole event and each individual recipi-
ent. Pediatric donors and recipients were defined as being 0- 17 years of age. Analysis was 
undertaken to characterize potential disease transmission from pediatric donors to adult 
or pediatric recipients and also to evaluate potential transmission from all donors to pedi-
atric recipients. P/P cases were further analyzed. A total of 5238 pediatric deceased US 
donors accounted for 17 456 organ transplants during the study period; 103 PDDTE re-
ports arose from these donors (2.0%). PDDTE were characterized as P/P (15%), possible 
(13%), IWDT (9%), unlikely, and excluded (63%). Disease was transmitted to 22 of 54 po-
tentially exposed (adult and pediatric) recipients with six attributable deaths. An infectious 
pathogen accounted for 13/15 of the P/P PDDTE associated with pediatric donors, af-
fecting 19 of 50 potentially exposed recipients and resulting in five deaths. Four separate 
viral pathogens from six donors accounted for P/P transmissions to 11 recipients with the 
unanticipated transmission of CMV most common. No pediatric donor transmitted HIV, 
HBV, or HCV. Bacteria, fungi, and parasites accounted for three (all staphylococci), three 
(Zygomycetes and Histoplasma), and two (both Toxoplasma) P/P transmissions from seven 
donors, respectively. From the recipient side, 11/11,188 pediatric recipient deceased and 
living donor transplants during the study period were associated with a P/P PDDTE 
(<0.1%) with infectious pathogens accounting for 9/11 P/P events. Infections were split 
among pathogen categories (bacteria 2, viruses 3, parasites 3, and fungi 1). Reporting rates 
of PDDTE involving pediatric donors were very low and similar to rates from all donors, 
with resulting P/P transmissions occurring in only 0.1% of exposed recipients, but trans-
missions were associated with six deaths. Rates of P/P transmission to pediatric recipients 
from any donor (<0.1%) were also very low and similar to that of all recipients. Additional 
studies are needed to compare the pattern and outcome of donor- derived disease trans-
mission from and to pediatric and adult donor and recipients.
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1  | INTRODUCTION
The UNOS is the private, non- profit organization that manages the 
United States’ organ transplant system under the OPTN contract with 
HRSA. Since 2005, OPTN policy has required reporting of all unantic-
ipated PDDTE in support of efforts to track, understand, and learn 
from donor- derived disease transmission events in the United States.1 
Since 2008, reported PDDTE have been reviewed by the OPTN Ad Hoc 
DTAC.2 Since that time, the DTAC has worked to learn from this expe-
rience to enhance the transplant community’s understanding of donor- 
derived diseases and continually refine OPTN policies requiring reporting 
of PDDTE and communication between OPOs and transplant centers. 
While a growing number of publications and guidance documents have 
been generated through ongoing efforts to learn from this experience, 
neither the specific evaluation of potential transmissions from pediatric 
donors nor the impact of donor- derived disease transmissions on pedi-
atric organ recipients has been previously undertaken. This study was 
carried out to address these issues.
2  | METHODS
This study used data from the Organ Procurement and Transplantation 
Network (OPTN). The OPTN data system includes data on all donors, 
wait- listed candidates, and transplant recipients in the United States, sub-
mitted by the members of the Organ Procurement and Transplantation 
Network (OPTN) and has been described elsewhere. The HRSA, US 
Department of Health and Human Services, provides oversight to the 
activities of the OPTN contractor. OPTN policy requires reporting of 
unexpected PDDTE to its Improving Patient Safety port (housed with 
UNetSM) by either transplant hospitals or the OPOs.3 Once submitted, 
potential transmission events are initially screened by OPTN staff and 
additional details sought before undergoing formal review by the full 
DTAC following previously published processes and procedures.4 For 
each reported PDDTE, the DTAC assessed the likelihood that transmis-
sion had occurred as either proven, probable, possible, unlikely, excluded, 
or IWDT (typically an antimicrobial being given to prevent development 
of infection) for all recipients of a given donor.4 The committee’s assess-
ment for potential event included an overall assessment for a PDDTE 
based on the highest level (eg, proven vs possible) assigned to any of the 
potentially exposed recipients (eg, if one recipient experienced a proven 
transmission, the overall assessment would be proven regardless of the 
outcome for other recipients) as well as providing individual assessments 
for all recipients. Once all individual recipient assessments and the over-
all assessment were assigned for each PDDTE, this information was re-
corded in the OPTN DTAC database.
All cases reported to and assessed by the DTAC between 2008 
and 2013 were included in this review. Potential pediatric cases were 
defined as involving either a donor or recipient less than 18 years of 
age. The DTAC database was reviewed to identify PDDTE involving a 
pediatric deceased donor of organs to adult or pediatric recipients as 
well as cases involving any age donor to pediatric recipients. All PDDTE 
were considered within the confines of confidential medical peer review. 
Because of this, the DTAC is not permitted to provide specific details for 
any given single potential transmission event or to provide details for 
any disease type where only a single report was received during the year. 
PDDTE classified as either proven or probable as well as those catego-
rized as unlikely or excluded were combined for the purpose of analysis.
3  | RESULTS
An overview of donor- derived disease from pediatric donors to all re-
cipients is summarized in Figure 1. A total of 5238 pediatric deceased 
donors accounted for 17 456 organ transplants during the study pe-
riod with 11 393 going to adult recipients and 6064 to children; 103 
PDDTE reports were submitted to the OPTN Improving Patient Safety 
Portal involving these donors (2%). The overall evaluation by the DTAC 
classified 15 of these PDDTE as proven/probable for an overall rate 
of 0.3% of pediatric donors being associated with a proven/probable 
donor- derived disease transmission event. Of the remaining PDDTE, 13 
were assessed to be possible, nine to be IWDT, and 66 to be unlikely/
excluded. The 15 proven/probable cases were assessed as resulting in 
transmission to 22 of 54 total (both pediatric and adult) exposed recipi-
ents, which represents transmission to 0.1% of all transplant recipients 
with pediatric organs. Infections accounted for 13/15 proven/probable 
PDDTE; transmission of a malignancy and a peanut allergy accounted for 
the remaining two proven/probable events. As summarized in Figure 1, 
viral infections were the most commonly transmitted class of pathogens 
affecting 11 recipients from six donors. Cytomegalovirus (CMV) was the 
most commonly transmitted virus accounting affecting four recipients 
from three donors. Two of the donors were teenagers while the other 
donor was younger. CMV would be considered an unanticipated PDDTE 
in situations where both the donor and recipient pretransplant serolo-
gies were negative. Despite 277 pediatric deceased donors identified as 
PHS increased risk during the period, no transmissions involving hepa-
titis (B or C) or HIV from a pediatric donor occurred during the study 
period. Bacteria, fungi, and parasites accounted for three (all staphylo-
cocci), two (Zygomycetes and Histoplasma), and two (both Toxoplasma) 
donor transmissions, respectively. Disease transmission was assessed as 
causing six deaths in two pediatric and four adult recipients. Five of the 
deaths were attributed to transmission of an infectious pathogen from 
four donors (Toxoplasma, Zygomycetes, Balamuthia, and LCMV) and one 
death was due to transmission of a malignancy, resulting in an attribut-
able death rate due to a donor- derived transmission event of 0.03% of 
all transplant recipients of pediatric organs.
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A summary of donor- derived disease occurring in pediatric recip-
ients from any donor is shown in Figure 2. A total of 11 188 children 
received an organ from either an adult or pediatric donor during the 
study period. Eleven pediatric organ recipients experienced a proven/
probable PDDTE (0.1%) with infectious pathogens accounting for 
9/11 of the proven/probable transmission events. Infections were 
evenly split among pathogen categories (viruses 3, bacteria 2, para-
sites 3, and fungi 1) with eight different pathogens accounting for the 
nine proven/probable infectious transmissions. Pathogens specifically 
associated with transmission included CMV, HBV, HTLV2, Pseudomonas 
aeruginosa, Mycobacterium tuberculosis, Strongyloides, Toxoplasma (2 
separate donors to 2 recipients), and Histoplasma. The remaining two 
proven/probable PDDTE were attributable to a malignancy and a pea-
nut allergy. Proven/probable PDDTE occurred in five liver recipients (2 
bacterial and 2 viral infection as well as the peanut allergy), four heart 
recipients (1 viral, 1 fungal, and 2 parasites), two lung recipients (1 fungal 
infection and 1 malignancy), and one kidney recipient (parasitic infection). 
Overall, proven/probable transmission events accounted for two deaths 
in pediatric recipients for an attributable death rate of 0.02% of all pedi-
atric organ recipients during the study period. Of note, these two fatal 
transmissions were the two fatal transmission cases noted from pediatric 
donors.
4  | DISCUSSION
The importance of the donor as a source of infection in organ recipi-
ents was recognized early in the history of transplantation. Seminal 
observations of the critical role of the donor as a major source of 
cytomegalovirus and Epstein- Barr virus eventually led to the rec-
ognition of a distinction between anticipated (for which one could 
potentially develop preventive strategies against and at a minimum 
provide specific consul to organ recipients and their family about 
the presence of risk) and unanticipated donor- derived infections. 
Additional observations also identified the potential for transmis-
sion of malignancies and even allergies from the donor to one of 
more recipients. As occurrences of high- profile donor- derived trans-
missions of pathogens including HIV,5 HCV,5 rabies,6 and West Nile 
Virus7,8 were reported, the need for systematic tracking of potential 
donor- derived infections and other donor- derived diseases became 
increasingly recognized. In the USA, this was accomplished through 
mandated reporting of PDDTE to the OPTN and the creation of the 
OPTN Ad Hoc Disease Transmission Advisory Committee and the 
development of its now well- established processes and infrastruc-
ture. Additional efforts have been initiated by a number of individual 
countries and by the World Health Organization (Project NOTIFY).9 
Taken together, these efforts share a common goal of enhancing 
the safety of transplant recipients through a better understanding 
of potential risks for disease transmission and have resulted in the 
enhanced awareness of the transplant community of the importance 
of the potential for and clinical consequences of donor- derived dis-
ease transmission, informing changes in both policy and the clinical 
practice of transplantation. However, while disease transmission 
events involving pediatric donors and pediatric recipients have been 
included in prior aggregate analyses, specific evaluation for unique 
characteristics of disease derived from pediatric donors or spectrum 
F IGURE  1 Donor- derived disease from pediatric donors: 2008- 2013
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and impact of donor- derived disease on pediatric recipients have 
not been previously studied. Accordingly, the results of the current 
study are both informative and reassuring in that the incidence and 
outcome of donor- derived disease transmission events appear to 
be similar when one compares both pediatric and adult donors and 
recipients.
The results of the current study identified that reported rates of 
PDDTE involving pediatric donors were very low (2%) with proven/
probable transmissions from pediatric donors occurring in only 0.1% 
of recipients (either adult or pediatric). The cumulative incidence rate 
of reported PDDTE was 1.9% for deceased donors (adult and pediat-
ric) reported to the OPTN through 2013 involving donors recovered in 
2008- 2012 although the overall rate for all donors (deceased and liv-
ing) was 1.1%.4 The rate of proven/probable transmission during this 
time period was 0.4% and 0.2% from deceased donors (adult and pe-
diatric) and all donors (living and deceased), respectively.4 As children 
are rarely if ever used as living donors, comparison of both the rate of 
PDDTE reporting and that of proven/probable transmission between 
pediatric and all deceased donors would seem most appropriate. 
Based upon these comparisons, the current results suggest that rates 
of both reporting a potential PDDTE and of a proven/probable trans-
mission were similar for pediatric and adult deceased donors during 
this time period.
Five proven/probable disease transmission events from a pediatric 
donor were assessed as causing six deaths (2 in pediatric and 4 in adult 
recipients) in this study for an attributable mortality rate of 0.03% of 
all recipients of pediatric organs. Five of the six deaths were associ-
ated with the transmission of an infectious pathogen, and one was 
due to transmission of a malignancy. Two pediatric recipients were 
assessed as dying secondary to a donor- derived transmission (both 
from pediatric donors) for an attributable mortality rate of 0.02%. In 
comparison, analysis of proven/probable disease transmission from all 
deceased donors (adult and pediatric) during this time period identi-
fied 39 deaths affecting the 110 402 recipients transplanted for an 
attributable mortality rate of 0.04%. Accordingly, rates of attributable 
mortality due to proven/probable disease transmission appear to be 
similar in both the adult and pediatric donor and recipient populations.
Infectious pathogens accounted for 13 of 15 (87%) of proven/
probable donor- derived transmission events from pediatric donors 
during this study period. Viral pathogens accounted 46% of these 
transmissions, but important transmission events also occurred due 
to bacteria, fungi, and parasites. In comparison, in a cohort including 
all donors (but largely adult donors), viral infections accounted for 42 
of 219 (19%) of transmission with 19 hepatitis C or hepatitis B trans-
missions, pathogens not transmitted from our pediatric cohort despite 
the fact that it included 277 donors identified as PHS increased risk. 
Further malignancies and non- infectious events accounted for the 
largest percentage of adult donor transmission events (30%) and the 
largest number of fatal donor transmissions, but were very uncommon 
in the pediatric population.10
Limitations include the reliance of all recipient centers and OPOs 
to report suspected donor- derived diseases for review through what 
is a passive reporting system. In addition, the data for the DTAC mem-
bers to review are limited to deidentified information with follow- up 
generally confined to 45 days after the event. Accordingly, some cases 
may have been either under- or overclassified.
In summary, reported rates of PDDTE involving pediatric donors 
were very low and similar to rates from all donors, with resulting 
F IGURE  2 Donor- derived disease in pediatric recipients: 2008- 2013
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P/P transmissions occurring in only 0.1% of exposed recipients, 
but transmissions were associated with six deaths. Rates of P/P 
transmission to pediatric recipients from any donor (<0.1%) were 
also very low and similar to that of all recipients. Additional studies 
are needed to compare the pattern and outcome of donor- derived 
disease transmission from and to pediatric and adult donor and 
recipients.
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